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Abstract 
BACKGROUND: Detection of minimal residual disease (MRD) in the early phase of therapy is the most powerful 
predictor of relapse risk in children with acute lymphoblastic leukaemia (ALL).  
AIM: We aimed to determine the significance of MRD at the end of remission induction therapy in the prediction of 
treatment outcome in children with ALL.  
METHODS: Sixty-four consecutive patients aged 1-14 years with newly diagnosed ALL were enrolled in this study 
from January 2010 to October 2017. All patients were treated according to the ALL IC BFM 2002 protocol. MRD 
was detected at the end of remission induction therapy (day 33) by multiparameter 6-colour flow cytometry 
performed on bone marrow specimens with a sensitivity of 0.01%.  
RESULTS: Overall, 42.2% of patients had detectable MRD on day 33 of therapy. MRD measurements were not 
significantly related to presenting characteristics but were associated with a poorer blast clearance on day 8 and 
15 of remission induction therapy. Patients with negative MRD status on day 33 had a 5-year event-free survival 
of 94.6% compared with 76.1% for those with positive MRD status (P = 0.044).  
CONCLUSION: MRD levels at the end of remission induction therapy measured by multiparameter flow cytometry 
have clinical significance in childhood ALL. High levels of MRD are strongly related to poor treatment outcome. 
 
 
 
 
Introduction 
 
Minimal residual disease (MRD) is defined as 
the presence of sub-microscopic levels of leukaemic 
cells. [1] Detection of MRD during remission induction 
and consolidation therapy is the most sensitive 
method to evaluate treatment response and one of the 
strongest predictors of outcome in childhood acute 
lymphoblastic leukaemia (ALL). Many studies have 
demonstrated the prognostic significance of 
measuring MRD in childhood ALL, suggesting that 
MRD positivity at serial time points during the 
treatment is highly predictive of relapse, and it is 
associated with poor treatment outcome [2], [3], [4], 
[5], [6], [7], [8], [9]. 
Current contemporary protocols incorporate 
MRD monitoring as the main stratification criterion for 
risk-adapted treatment. Recent studies have shown 
that personalised treatment based on MRD can 
improve the clinical outcome of children with ALL [16], 
[17], [18], [19], [20], [21]. Because of the strong 
correlation between MRD levels and risk of relapse, 
this concept includes treatment intensification for 
children with higher MRD levels and treatment de-
intensification for patients with early MRD clearance. 
The techniques for MRD assessment allow an 
average detection of one leukemic cell among 10
4
 to 
10
5
 normal cells, which represents a 100-fold increase 
in sensitivity compared to conventional bone marrow 
Jovanovska et al. Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Sep 15; 7(17):2818-2823.                                                                                                                                                2819 
 
cytomorphology. The most widely used methods for 
MRD assessment are multiparameter flow cytometric 
(FCM) analysis of aberrant immunophenotypes and 
polymerase chain reaction (PCR) amplification of 
different fusion genes transcript or the antigen 
receptor rearrangements for immunoglobulin (Ig) or 
the T-cell receptors (TCR). [10], [11], [12], [13], [14], 
[15]. Both methods are highly sensitive and specific, 
but expensive, complex, require qualified staff and, 
because of that, their use is restricted in countries with 
limited resources.  
The purpose of our study was to determine 
the prognostic significance of MRD detected by flow 
cytometry at the end of remission induction therapy in 
children with ALL.  
 
 
Material and Methods 
 
Patients and treatment 
From January 2010 to October 2017, 74 
consecutive patients aged 1 to 14 years with newly 
diagnosed ALL were treated at the Department of 
Hematology and Oncology of the University Clinic for 
children’s diseases in Skopje, Macedonia. Among the 
74 patients, 64 patients in whom flow cytometric MRD 
assessment was done on day 33 of remission 
induction were enrolled in this study. Data on 
demographic characteristics, diagnostic 
immunophenotyping, molecular risk factors, early 
treatment response, flow cytometric MRD assay and 
treatment outcomes were retrospectively collected 
from the hospital electronic system and paper-based – 
medical records. The study was approved by the 
Ethics Committee of the Medical Faculty in Skopje.  
Diagnosis of ALL was based on standard 
morphologic, cytochemical, immunophenotype and 
genetic studies. Patients were treated based on the 
intermediate-risk arm of ALL-IC BFM 2002 protocol 
consisted of induction (protocol I), consolidation 
(protocol M), delayed intensification (protocol II) and 
maintenance therapy with a total duration of 2 years. 
Induction chemotherapy consisted of glucocorticoids, 
vincristine, daunorubicin and L-asparaginase with 
intrathecal methotrexate. In protocol M all patients 
received four courses of high dose (5gr/m
2
) 
methotrexate. Eight children in our cohort (2 children 
with BCR-ABL positive ALL and 6 with high positive 
levels of MRD at the end of induction therapy) were 
allocated into a high-risk group, and they were treated 
according to the high-risk arm of ALL – IC BFM 2002 
protocol. One of the 2 patients with BCR-ABL positive 
ALL was treated with intensive chemotherapy alone, 
whereas the second patient was treated with 
chemotherapy plus imatinib. Informed consent had 
been obtained for all patients from their guardians 
before initiation of chemotherapy following The 
Declaration of Helsinki. 
 In Macedonia flow cytometry, which is 
performed at the Clinic of Hematology, is used in 
diagnosis for acute leukaemia, but its applicability in 
MRD assessment is limited. MRD analysis at the end 
of induction therapy (day 33) was performed in the 
reference flow cytometric laboratory of the General 
Hospital George Papanikolaou in Thessaloniki, 
Republic of Greece by multiparameter 6 color flow 
cytometry using bone marrow mononucleated cells 
which were sent immediately after bone marrow 
aspiration (sternum puncture) collected in 
ethylenediamine tetra-acetic acid tube. Leukaemia-
associated immunophenotypes were investigated with 
various combinations of monoclonal antibodies 
conjugated to the following fluorochromes: fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), 
allophycocyanin (APC), phycoerythrin-cyanin 5.1 
(PC5), phycoerythrin-cyanine 7 (PE Cy7) and 
allophycocyanin‐cyanine 7 (APC-Cy7), (Table 1 and 
2).  
Table 1: Monoclonal antibody combinations used for MRD 
detection in precursor B ALL 
FITC PE APC PC5 PECy7 APC-Cy7 
CD58 CD38 CD10 CD45 CD34 CD19 
CD24 CD38 CD10 CD45 CD34 CD19 
CD38 CD22 CD10 CD45 CD34 CD19 
CD81 CD20 CD10 CD45 CD34 CD19 
CD38 CD200 CD10 CD45 CD34 CD19 
 
Cell staining was performed on FACSCanto II 
flow cytometer, using the FACSDiva software (BD 
Biosciences) for analysis. This detection method 
allows the identification of one leukemic cell among 10 
000 or more normal bone marrow cells. MRD positivity 
was defined as ≥ 0.01% of mononuclear cells 
expressing leukaemia-specific immunophenotypes [3]. 
Table 2: Monoclonal antibody combinations used for MRD 
detection in T cell ALL 
FITC PE APC PC5 PECy7 APC-Cy7 
CD7 CD1a CD3 CD5 CD34 CD45 
CD38 CD1a CD3 CD5 CD34 CD45 
CD99 CD1a CD3 CD5 CD34 CD45 
 
Statistical analysis  
October 31, 2018, was chosen as the 
reference date for the collection of data. The mean 
observation time was 45.7 months (range 1-100 
months). Associations between MRD, presenting 
features, and early treatment response was analysed 
with the 
2
 test or Fisher exact test. Event-free 
survival (EFS) was calculated from the date of 
diagnosis to date of first event or date of last follow up 
if no event occurred. The event was resistance to 
therapy, relapse or death from any cause. EFS and 
survival curves were estimated according to Kaplan-
Meier and groups were compared by log-rank test. 
The significance level of 0.05 was used in all 
statistical test. All statistical analyses were performed 
using SPSS (Statistical Package for the Social 
Science) version 23.0. 
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Results 
 
Patients’ characteristics 
Presenting clinical features of the 64 patients 
were summarised in Table 3. The median age of 
patients was 5.6 years (range 1-14 years). There was 
a slight predominance of males (57.8%). The median 
WBC count at presentation was 32.07 x 10
9
/L (range 
0.89-194.3 x 10
9
/L). Precursor B cell ALL was 
diagnosed in 52 (81.2%) patients and T cell ALL in 12 
(18.8%). CNS involvement at diagnoses was 
confirmed in 3 (4.7%) patients. The majority of 
patients were considered as standard risk based on 
NCI criteria. BCR-ABL was documented in 2 out of 45 
patients.  
 
Relation among MRD levels, presenting 
 features, and early treatment response 
Of the 64 patients, 37 (57.8%) had a bone 
marrow that was negative for MRD (< 0.01%), 
whereas 27 (42.2%) were MRD positive (≥ 0.01%) at 
the end of remission induction therapy. Among 
patients with MRD positive status, the levels of MRD 
were 0.01-≤ 0.1% in 11 (40.8%) children, 0.1-≤ 1% in 
12 (44.4%) patients and >1% in 4 (14.8%) patients. 
Regarding MRD distribution by immunophenotype, we 
observed a higher rate of MRD positive findings 
among patients with precursor B cell ALL compared to 
patients with T cell ALL (44.2% versus 33.3% 
respectively), but it should be noted that quantitative 
MRD levels were higher in T cell ALL.  
Table 3: MRD distribution according to patients' 
clinicobiological features 
Characteristics 
Total MRD level on day 33 P 
< 0.01% ≥ 0.01% 
 64 (%) 37 (%) 27 (%)  
Gender    0.523 
male 37 (57.8) 21 (56.8) 16 (59.3)  
female 27 (42.2) 16 (43.2) 11 (40.7)  
Age    0.194 
1 to < 10 56 (87.5) 34 (91.9) 22 (81.5)  
10 -14 8 (12.5) 3 (8.1) 5 (18.5)  
WBC count (x 10
9
/L)    0.615 
≤ 50 x10
9
/L 52 (81.2) 30 (81.1) 22 (81.5)  
> 50 x 10
9
/L 12 (18.8) 7 (18.9) 5 (18.5)  
Immunophenotype    0.362 
Precursor B-ALL 52 (81.2) 29 (78.4) 23 (85.2)  
T cell-ALL 12 (18.8) 8 (21.6) 4 (14.8)  
CNS involvement     
present 3 (4.7) 2 (5.4) 1 (3.7)  
absent 61 (95.3) 35 (94.6) 26 (96.3)  
NCI risk group    0.329 
standard 48 (75.0) 29 (78.4) 19 (70.4)  
high 16 (25.0) 8 (21.6) 8 (29.6)  
BCR-ABL     
positive 2 (3.1) 0 (0) 2 (7.4) 0.151 
negative 43 (67.2) 24 (64.9) 19 (70.4)  
unknown 19 (29.7) 13 (35.1) 6 (22.2)  
Prednisone response    0.019 
PPR 7 (10.9) 1 (2.7) 6 (22.2)  
PGR 57 (89.1) 36 (97.3) 21 (77.8)  
BM - 15 day    0.003 
М1 45 (70.3) 32 (86.5) 13 (48.2)  
М2 14 (21.9) 4 (10.8) 10 (37.0)  
М3 5 (7.8) 1 (2.7) 4 (14.8)  
Abbreviations: WBC = white blood cells; CNS = central nervous system; NCI = National 
Cancer Institute; NCI standard risk group = age 1 to <10 years, and WBC < 50 x  10
9
/L; 
NCI high risk group= age ≥ 10 years or WBC > 50 x 10
9
/L; PPR= absolute blast count in 
the peripheral blood ≥ 1 x 10
9
/L; PGR = absolute blast count in the peripheral blood less 
than 1 x 10
9
/L after 7 days of prednisone and one dose of intrathecal methotrexate on day 
1; M1 BM (bone marrow) = < 5%, M2 = 5 to 25% and M3 = ≥ 25% leukemic blasts in BM. 
 
Table 3 shows the relation between levels of 
MRD on day 33 and the clinicobiological features of 
the disease. In our analysis, the presenting features 
including gender, age, WBC count at diagnoses, CNS 
involvement, immunophenotype, NCI risk status and 
molecular risk factors did not differ significantly 
between patients with negative and positive MRD 
status at the end of induction therapy. Two cases with 
BCR-ABL positive ALL, which is prognostically 
unfavourable had ≥ 0.1% leukemic cells at the end of 
remission induction, but this failed to reach statistical 
significance due to small sample size (P = 0.151). 
These findings indicate that presenting prognostic 
features could not identify patients who will have 
undetectable MRD at the end of remission induction 
therapy. We also tested whether earlier treatment 
response determined by prednisone response and 
bone marrow morphology on day 15 would predict the 
presence of MRD after completion of induction 
therapy. In our series, MRD levels differed 
significantly between prednisone poor and good 
responders. Patients with prednisone poor response 
(PPR) were more likely to be MRD positive at day 33 
than patients with prednisone good response (PGR) 
(P = 0.019). Bone marrow morphology on day 15 also 
had a significant impact of MRD status on day 33. 
Patients with M2 and M3 bone marrow morphology on 
day 15 were more likely to be MRD positive at the end 
of induction therapy than patients with M1 (P = 0.003). 
In contrast to presenting clinical features, our findings 
indicate that the earlier clearance of leukemic blasts in 
peripheral blood and bone marrow could predict 
patients who will attain negative MRD status at the 
end of remission induction therapy. 
When comparing 2 groups of patients based 
on end-induction MRD status, 27 MRD positive 
patients on day 33 had a significantly lower 5-year 
EFS than 37 MRD negative patients (76.1% versus 
94.6; respectively, P = 0.044; Figure 1). The main 
event in our series that contributed to the EFS was the 
occurrence of relapse. Relapses were recorded in 8 
(12.5%) out of a total of 64 patients. Among patients 
with positive MRD findings, the relapse rate was 
22.2% compared to 5.4% among MRD negative 
patients (Table 4). Of note, none of the MRD negative 
patients with precursor B cell ALL experienced 
relapse during the follow-up study period. Thus, 
relatively rapid elimination of MRD in patients with this 
subtype of leukaemia identifies cases with an 
excellent prognosis. 
Table 4: Description of events contributing to EFS comparing 
MRD negative and positive patients 
 MRD negative patients 
N = 37 
MRD positive patients 
N = 27 
Events N (%) N (%) 
Isolated BM relapse 2 (5.4) 5 (18.5) 
Combined relapse (BM+CNS) 0 1 (3.7) 
Death in remission 0 2 (7.4) 
Total deaths 2 (5.4) 7 (25.9) 
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Discussion 
 
The prognostic importance of MRD in 
childhood ALL is well established in numerous clinical 
studies [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], 
[13], [14], [15]. Modern treatment protocols for 
childhood ALL recommended MRD monitoring at 
multiple time points to evaluate the effectiveness of 
chemotherapy in the elimination of leukemic cells. 
Complex and sophisticated methods such as PCR-
based techniques or multiparametric flow cytometry 
have been developed and evaluated to detect MRD. 
MRD measurement during the early phase of 
treatment (on day 8 and day 15/19) and at the end of 
induction therapy (day 29, 33 or 42) is considered the 
main predictor of treatment outcome and essential 
tool for risk stratification, aimed at both treatment 
intensification and reduction [8], [9], [10], [11], [12], 
[13], [14], [15], [23], [24], [25]. 
Patients with less than 0.01% leukemic cells 
at the end of remission induction are likely to have an 
excellent treatment outcome, whereas patients with 
high levels (i.e., ≥ 1%) of MRD at the end of the 
induction phase have a significantly higher risk of 
relapse and should be considered for alternative 
treatments. [3,4,8] Recent studies have demonstrated 
that intensification of therapy for patients with high 
levels of MRD can improve their outcome [12], [15]. 
 
Figure 1: Kaplan-Meier estimate of 5-year Event-free survival based 
on MRD status on day 33 (negative versus positive) EFS = 94.6% 
versus 76.1% respectively, P = 0.044 
 
In this study, MRD measurement was 
performed at the end of induction therapy, as this time 
point seemed most relevant for the treatment 
decision. Our date defines a cohort of 37 patients with 
negative MRD status at the end of induction therapy 
who have a superior EFS compared to those with 
positive MRD and this finding is consistent with 
numerous clinical studies [2], [3], [5], [6], [7], [8], [10], 
[12], [13], [14], [15], [23]. Researchers of Children’s 
Oncology Group (COG) studied the prognostic impact 
of MRD measured by flow cytometry in the peripheral 
blood at day 8, end-induction (day 29) and end-
consolidation bone marrows in 2143 children with 
precursor B-cell ALL. The presence of MRD in day-8 
blood and day-29 bone marrow was associated with a 
lower EFS in all risk groups; even patients with 0.01% 
to 0.1% day-29 MRD had poor outcome compared to 
MRD negative patients at the end of remission 
induction (5-year EFS 59% vs 88%) [8]. In the AIEOP 
– BFM ALL 2000 study, 3184 patients with precursor 
B cell ALL were stratified by MRD measured on days 
33 and 78 based on immunoglobulin and TCR gene 
rearrangements into three groups with a significantly 
different outcome. Patients defined as standard risk 
(42%) showed a 5-year EFS estimated at 92.3%, 
while intermediate (52%) and high-risk patients (6%) 
showed a 5-year EFS of 77.6% and 50.1%, 
respectively [10] In the study by Basso et al. 
measurement of MRD by flow cytometry on day 15 
bone marrow was the most powerful early predictor of 
relapse. Standard risk patients had a significantly 
lower 5-year cumulative incidence of relapse 
compared to patients from the intermediate and high-
risk group (7.5% vs 17.5 vs 47.2%, respectively) [9]. 
In our cohort, certain clinicobiological features 
of ALL didn’t show relation to the speed of leukemic 
blasts reduction. Investigators of Total Therapy 
studies XIIIA and XIIIB at St. Jude Children's 
Research Center have shown that the patient`s age 
and the presence or absence of adverse genetic 
abnormalities were directly related to the speed and 
extent of initial cytoreduction [3]. And other study 
groups have observed slow clearance of MRD in NCI 
high-risk children, or with leukemic blasts expressing 
BCR-ABL [2], [26]. In our cohort, the BCR-ABL fusion 
transcript was confirmed in two patients, and both of 
them were MRD positive at high levels at the end of 
induction therapy. Despite the lack of statistical 
significance, probably due to the small sample size, it 
can be said that our results are in agreement with the 
previous studies [2], [3], [26]. MRD clearance is 
depended by the biology of the leukemic blasts, but 
other factors as well including specific host germline 
pharmacogenetics polymorphisms can affect in vivo 
treatment response and regulate treatment efficacy in 
each patient [27]. 
Prednisone response and bone marrow 
morphologic evaluation on day 15 are an integral part 
of the BFM protocol`s stratification scheme. Prediction 
of treatment outcome by conventional morphological 
assessment of treatment response is still of great 
importance, especially to countries with limited 
resources for MRD monitoring [28]. Our study 
confirmed a significant association between rapid 
early clearance of leukemic cells from peripheral 
blood and bone marrow and attaining MRD negative 
status at the end of induction therapy. This is in 
agreement with the previous study of Fronkova et al., 
who observed that in patients treated according to 
ALL IC BFM 2002 protocol, MRD negativity at day 33 
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was associated with good prednisone response and 
non – M3 morphology at day 15 [29]. Researching 
whether it is possible to avoid MRD testing in some 
subgroups of ALL patients, Fronkova et al., found that 
morphological criteria in ALL-IC are able to identify 
most MRD high-risk patients, but fail to define the 
MRD low-risk group, for who is possible treatment 
reduction to avoid long-term toxicities, which is the 
challenge of modern leukaemia treatment [29]. 
In conclusion, measurement of blast 
clearance allowing the quantitative definition of MRD 
is a mandatory tool for favourable treatment outcome 
of childhood ALL. Our study confirmed the excellent 
outcome for childhood ALL in patients with negative 
MRD monitoring by flow cytometry at the end of 
induction therapy. MRD assessment is still not 
available in our treatment centre and considering its 
prognostic importance; there is an urgent clinical need 
to introduce in routine practice.  
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